Can we predict who is at risk of facing cognitive issues in PD and address them earlier? These are the questions being pursued by Dr. Goldman of the PDF Research Center at Rush University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
ESCRT mediated uptake and degradation of brain targeted ?-synuclein-single chain antibody attenuates neuronal degeneration in vivo.
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
Mol Ther 2014 Jul;
Authors: Brian Spencer, Sharareh Emadi, Paula Desplats, Simona Eleuteri, Sarah Michael, Kori Kosberg, Jay Shen, Edward Rockenstein, Christina Patrick, Anthony Adame, Tania Gonzalez, Michael Sierks, Eliezer Masliah
Parkinson's disease and Dementia with Lewy bodies are neurodegenerative disorders characterized by accumulation of ?-synuclein. Recently, single chain antibodies (scFV) have been developed against individual conformational species of ?-syn. Unlike more traditional mAbs, these scFVs will not activate or be endocytosed by Fc receptors. For this study, we investigated a scFV directed against oligomeric ?-syn fused to the LDL receptor-binding domain from apoB. The modified scFV showed enhanced brain penetration and was imported into neuronal cells through the ESCRT pathway leading to lysosomal degradation of ?-syn aggregates. Further analysis showed the scFV was effective at ameliorating neurodegenerative pathology and behavioral deficits observed in the mouse model of DLB/PD. Thus the apoB modification had the effect of both increasing accumulation of the scFV in the brain and directing scFV/ ?-syn complexes for degradation through the ESCRT pathway leading to improved therapeutic potential of immunotherapy.Molecular Therapy (2014); doi:10.1038/mt.2014.129.
PMID: 25008355 [PubMed - as supplied by publisher]